Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib in Adult Gliomas
NCT01229644Phase 2Terminated
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Apr 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of crenolanib in glioma (3 cohorts), sponsored by AROG Pharmaceuticals, Inc. Primary endpoint: Overall Response Rate. Started Apr 2011; status: terminated.
02
Drugs
crenolanib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT01229644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01229644.